Disease-causing IgE antibodies are regulated to avoid allergic responses

April 23, 2014
Immunology: Subverting the sneeze
A delicate regulatory balance exists to keep IgE antibodies from causing allergic reactions. Credit: antpkr/iStock/Thinkstock

The immunoglobulin E (IgE) antibody released by the immune system is a pivotal defense against gut parasites and toxins. However, the same antibody when misdirected can also cause allergic responses to food or substances in the environment. An international team led by researchers at the A*STAR Singapore Immunology Network has now discovered a regulatory mechanism that keeps IgE levels in check.

A better understanding of the process of IgE production and how it can be subverted should enable scientists to develop the next generation of allergy treatments. "If we know the mechanism, potentially we could intervene therapeutically to prevent the development of severe allergic and anaphylactic reactions," says A*STAR immunologist Maria Curotto de Lafaille, who led the research.

A type of white blood cell known as a B cell can change the antibodies that it produces through a process known as immunoglobulin class switching. B that produce IgE can arise through one of two distinct switching mechanisms. Either the B cells go through a sequential process that involves another type of immunoglobulin, IgG, as an intermediary, or they take a direct route to IgE generation. The sequential process creates IgE with high affinity for antigens—the substances that can trigger an immune response and can cause severe . In contrast, the direct switching pathway produces IgE antibodies that bind their antigens weakly. These low-affinity antibodies can compete with the problematic IgE to prevent anaphylaxis.

The origin, functional properties and population dynamics of IgE-producing cells had been poorly understood. To track the dynamics of IgE production in a living system, Curotto de Lafaille and her colleagues created a new mouse strain that fluoresces whenever and wherever IgE antibodies are produced. Using the mouse model, the researchers showed that IgE-producing cells that undergo the direct switching pathway at germinal centers—sites in the lymphatic system where B cells differentiate and mutate to enhance their antigen binding—tend to get stuck in that developmental state and end up 'failing to thrive'. "These cells have a lot of defects and they end up dying," says Curotto de Lafaille.

The failure of the IgE cells to directly produce antibodies with strong binding ability imposes a strong constraint on IgE-based immune responses. "If you easily make so many high-affinity IgE cells, you'd be constantly in danger of life threatening reactions like anaphylaxis," Curotto de Lafaille explains. "That's why there's an evolutionary pressure to limit this process."

Explore further: Delayed allergy reactions seen with pediatric meat consumption

More information: He, J.-S., Meyer-Hermann, M., Xiangying, D., Zuan, L. Y., Jones, L. A. et al. "The distinctive germinal center phase of IgE+ B lymphocytes limits their contribution to the classical memory response." Journal of Experimental Medicine 210, 2755–2771 (2013). dx.doi.org/10.1084/jem.20131539

Related Stories

Researchers investigate nut allergy mechanisms

November 18, 2013

U.S. Department of Agriculture (USDA) scientists teamed with university collaborators to validate the ability of a database of allergenic proteins to predict when an individual will react to two or more different types of ...

Recommended for you

Nature study suggests new therapy for Gaucher disease

February 22, 2017

Scientists propose in Nature blocking a molecule that drives inflammation and organ damage in Gaucher and maybe other lysosomal storage diseases as a possible treatment with fewer risks and lower costs than current therapies.

Understanding how HIV evades the immune system

February 21, 2017

Monash University (Australia) and Cardiff University (UK) researchers have come a step further in understanding how the human immunodeficiency virus (HIV) evades the immune system.

T cells support long-lived antibody-producing cells

February 21, 2017

If you've ever wondered how a vaccine given decades ago can still protect against infection, you have your plasma cells to thank. Plasma cells are long-lived B cells that reside in the bone marrow and churn out antibodies ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.